Navigation Links
Amicus Therapeutics Announces Second Quarter 2009 Financial Results
Date:8/5/2009

ones and receipt of milestone payments from Shire. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD-G

     Table 1
                            Amicus Therapeutics, Inc.
                          (a development stage company)
                      Consolidated Statements of Operations
                                   (Unaudited)
                (In thousands, except share and per share amounts)


                                                                   Period from
                                                                   February 4,
                                                                       2002
                                                                   (inception)
                              Three Months          Six Months          to
                             Ended June 30,        Ended June 30,    June 30,
                             2008      2009        2008      2009      2009

    Revenue:
      Research revenue     $3,113     $4,667     $5,579     $8,580   $22,143
      Collaboration
       revenue                694        694      1,389      1,389     4,576
    Total revenue           3,807      5,361      6,968      9,969    26,719

    Operating Expenses:
      Research and
       development         
'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... COLORADO SPRINGS, Colo. , July 31, 2014 ... Seed Grant awardee today with $25,000 to fund ... the Foundation,s inception in 2011, the gift was ... 11 th Annual Meeting in ... physicians who specialize in neurointerventional approaches to neurovascular ...
(Date:7/31/2014)... NY (PRWEB) July 31, 2014 North Shore ... York City, partnered with GI Energy, one of the nation’s ... a $13 million upgrade of its 43-year-old CHP system. The ... and in an effort to extend the life of the ... generators and associated electrical and heat recovery equipment, while maintaining ...
(Date:7/31/2014)... 31, 2014 Senomyx , Inc. ... using proprietary taste science technologies to discover, develop, ... beverage, and ingredient supply industries, today reported financial ... ended the second quarter with $33.6 million in ... "During the past quarter Senomyx achieved another important ...
(Date:7/31/2014)... 31, 2014 Rancho BioSciences , ... of Omicsoft’s Array Suite with tranSMART . ... able to send data in tranSMART to Array Suite ... versions of tranSMART including the new 1.2 release. ... and storage for the analysis of high dimensional quantification ...
Breaking Biology Technology:SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3North Shore Towers Partners with GI Energy to Install Turnkey Natural Gas-Fired Combined Heat and Power Plant 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 14SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 15SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2014 FINANCIAL RESULTS 16Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 2Rancho BioSciences, in Partnership with Omicsoft, have Integrated Array Suite with tranSMART 3
... Symbol: MS, EDMONTON, Oct. 6 /PRNewswire-FirstCall/ - ... the treatment of multiple sclerosis (MS), today,announced that ... the,Company,s phase II MINDSET-01 trial of dirucotide (MBP8298) ... analysis and recommended,that the trial continue as per ...
... International,Corporation (Nasdaq: PRXL ) announced today it ... Stock Conference in New York, NY. James,Winschel, Senior ... making,a formal presentation on PAREXEL at 11:20 a.m. ... webcast of this presentation will be available under ...
... Oct. 6 Biocept, Inc. ("Biocept"), an,emerging leader in ... as CEO, President and Director and the appointment,of Edward ... of its former CEO, President and Director, Gordon F. ... a highly regarded professional,in our field, and believe he ...
Cached Biology Technology:BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board 2PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference 2Biocept, Inc. Announces CEO and Director Appointments 2
(Date:7/31/2014)... An international team of scientists from Spain, France, ... rove beetle that is the oldest definitive member ... found in amber. The discovery and description were ... phase-contrast X-ray synchrotron imaging technique, which allows the ... amber. The new species is described in the ...
(Date:7/31/2014)... the brain processes speech, potentially increasing the difficulty ... The University of Texas at Dallas. , In ... and Hearing , researchers demonstrated for the first ... recognition of speech sounds. , Noise-induced hearing loss ... an estimated 15 percent of Americans between the ...
(Date:7/31/2014)... was in full fury, raging swiftly from crown to ... of Yosemite National Park in California,s Sierra Nevada in ... began to turn, enacting a case study in the ... large, severe fires. , "When the Rim Fire hit ... been used as a management tool, rather than immediately ...
Breaking Biology News(10 mins):UT Dallas study reveals effect of loud noises on brain 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5
... June 22, 2011 Jerusalem, Israel The Israeli Chairmanship ... R&D and innovation, announced today in Jerusalem that since ... over 220 cooperative R&D projects have been approved and ... investment. Assembled in Jerusalem for the fourth and ...
... led by the University of Cambridge has found a ... in superstitious rituals and luck) in problem gamblers. ... National Problem Gambling Clinic, the researchers found that those ... susceptible to errors in reasoning associated with gambling, such ...
... The mechanics of instinctive behavior are mysterious. Even something ... can use its powerful sense of smell to detect ... before, has been almost totally unknown at the molecular ... Liberles, neuroscientists at Harvard Medical School, have discovered a ...
Cached Biology News:EUREKA invested over 300 million euros in industrial initiatives over the past year 2EUREKA invested over 300 million euros in industrial initiatives over the past year 3EUREKA invested over 300 million euros in industrial initiatives over the past year 4Betting on good luck and 4-leaf clovers 2The smell of danger 2The smell of danger 3
...
PURA Immunogen: PURA (NP_005850, 183 a.a. ~ 293 a.a) partial recombinant protein with GST tag. Storage: -20 C, Avoid Freeze/Thaw Cycles *Available for distribution in the US only...
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Phospho-CD18 (Ser756/Thr758/759) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
Biology Products: